Device Trial Radar · NCT07296263
Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Dec 30, 2025
Primary completion
Sep 15, 2026
Study completion Sep 15, 2026
Sponsor
- Lead sponsor
- HyperfineNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 22, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multi-center, interventional study designed to evaluate the visualization benefits of FDA approved gadolinium-based contrast agents (GBCAs) in portable magnetic resonance imaging (pMRI) of the brain. The study will enroll adult patients with known or suspected brain lesions involving blood-brain barrier disruption. Each participant will undergo a pre-contrast pMRI scan, receive an intravenous GBCA injection, and then complete a post-contrast pMRI scan using the Swoop® Portable MR Imaging® System. Lesion visualization will be assessed by independent neuroradiologists using standardized scoring criteria. The study will be conducted across a minimum of three sites to ensure diversity in patient population, imaging environments, and GBCA types.
Conditions
- Intra-axial Tumors
- Extra-axial Tumors
- Infection/Inflammatory Lesions
Interventions
Portable MRI (pMRI)Device
Portable magnetic resonance imaging (pMRI) performed using the Swoop® Portable MR Imaging® System (0.064 T), including acquisition of pre-contrast and post-contrast images.
Gadolinium-Based Contrast Agent (GBCA)Drug
Intravenous administration of an FDA-approved gadolinium-based contrast agent (GBCA) according to institutional standard-of-care dosing, administered between pre-contrast and post-contrast pMRI imaging.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiologist-rated lesion border delineation on post-contrast portable MRITime frame: 6 months
- Radiologist-rated lesion internal morphology visibility on post-contrast portable MRITime frame: 6 months
- Radiologist-rated degree of contrast enhancement of target lesions on portable MRITime frame: 6 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Neurology of Central Florida Research Center
Altamonte Springs, Florida
Massachusetts General Hospital
Boston, Massachusetts
Dent Neurologic Institute
Amherst, New York
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.